These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 26059710)

  • 41. Arsenic Trioxide-Coated Stent Is an Endothelium-Friendly Drug Eluting Stent.
    Zhao Y; Du R; Zhou T; Yang D; Huang Y; Wang Y; Huang J; Ma X; He F; Qiu J; Wang G
    Adv Healthc Mater; 2018 Aug; 7(15):e1800207. PubMed ID: 29770610
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pathological features of in-stent restenosis after sirolimus-eluting stent versus bare metal stent placement.
    Abe S; Yoneda S; Kanaya T; Oda K; Nishino S; Kageyama M; Taguchi I; Masawa N; Inoue T
    Cardiovasc Pathol; 2012; 21(2):e19-22. PubMed ID: 21489821
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biological effects of drug-eluting stents in the coronary circulation.
    Steffel J; Tanner FC
    Herz; 2007 Jun; 32(4):268-73. PubMed ID: 17607532
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characteristics of patients and types of lesions in patients with drug-eluting or bare-metal stent implantation in small coronary arteries: from the FU-Registry.
    Sugihara M; Miura S; Nishikawa H; Ike A; Mori K; Iwata A; Kawamura A; Saku K
    J Cardiol; 2013 Feb; 61(2):117-21. PubMed ID: 23159206
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Late-phase inflammatory response as a feature of in-stent restenosis after drug-eluting stent implantation.
    Yoneda S; Abe S; Kanaya T; Oda K; Nishino S; Kageyama M; Taguchi I; Masawa N; Inoue T
    Coron Artery Dis; 2013 Aug; 24(5):368-73. PubMed ID: 23744617
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents.
    Steinberg DH; Gaglia MA; Pinto Slottow TL; Roy P; Bonello L; De Labriolle A; Lemesle G; Torguson R; Kineshige K; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2009 Feb; 103(4):491-5. PubMed ID: 19195508
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Stent thrombosis in the era of drug eluting stents.
    Kawaguchi R; Angiolillo DJ; Futamatsu H; Suzuki N; Bass TA; Costa MA
    Minerva Cardioangiol; 2007 Apr; 55(2):199-211. PubMed ID: 17342038
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vascular pathology of drug-eluting stents.
    Nakazawa G; Finn AV; Virmani R
    Herz; 2007 Jun; 32(4):274-80. PubMed ID: 17607533
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis.
    Habara S; Iwabuchi M; Inoue N; Nakamura S; Asano R; Nanto S; Hayashi Y; Shiode N; Saito S; Ikari Y; Kimura T; Hosokawa J; Nakamura M; Kotani J; Kozuma K; Mitsudo K
    Am Heart J; 2013 Sep; 166(3):527-33. PubMed ID: 24016503
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug loaded nanoparticle coating on totally bioresorbable PLLA stents to prevent in-stent restenosis.
    Zhao J; Mo Z; Guo F; Shi D; Han QQ; Liu Q
    J Biomed Mater Res B Appl Biomater; 2018 Jan; 106(1):88-95. PubMed ID: 27875036
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and Efficacy of New Biodegradable Polymer-based Sirolimus-Eluting Stents in a Preclinical Model.
    Pérez de Prado A; Pérez Martínez C; Cuellas Ramón C; Regueiro Purriños M; López Benito M; Gonzalo Orden JM; Rodríguez Altónaga JA; Estévez Loureiro R; Benito González T; Viñuela Baragaño D; Molina Crisol M; Amorós Aguilar M; Pérez Serranos I; Vidal Parreu A; Benavides Montegordo A; Duocastella Codina L; Fernández Vázquez F
    Rev Esp Cardiol (Engl Ed); 2017 Dec; 70(12):1059-1066. PubMed ID: 28647315
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biofunctionalization of cardiovascular stents to induce endothelialization: Implications for in- stent thrombosis in diabetes.
    Marei I; Ahmetaj-Shala B; Triggle CR
    Front Pharmacol; 2022; 13():982185. PubMed ID: 36299902
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reduction-Responsive Nucleic Acid Delivery Systems To Prevent In-Stent Restenosis in Rabbits.
    Ye W; Chen Y; Tang W; Zhang N; Li Z; Liu Z; Yu B; Xu FJ
    ACS Appl Mater Interfaces; 2019 Aug; 11(31):28307-28316. PubMed ID: 31356048
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bioresorbable Vascular Scaffolds for Patients With In-Stent Restenosis: The RIBS VI Study.
    Alfonso F; Cuesta J; Pérez-Vizcayno MJ; García Del Blanco B; Rumoroso JR; Bosa F; Pérez de Prado A; Masotti M; Moreno R; Cequier A; Gutiérrez H; García Touchard A; López-Mínguez JR; Zueco J; Martí V; Velázquez M; Morís C; Bastante T; García-Guimaraes M; Rivero F; Fernández C;
    JACC Cardiovasc Interv; 2017 Sep; 10(18):1841-1851. PubMed ID: 28866036
    [TBL] [Abstract][Full Text] [Related]  

  • 56. How to accelerate the endothelialization of stents.
    Ong AT; Aoki J; Kutryk MJ; Serruys PW
    Arch Mal Coeur Vaiss; 2005 Feb; 98(2):123-6. PubMed ID: 15787303
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy.
    Curcio A; Torella D; Indolfi C
    Circ J; 2011; 75(6):1287-96. PubMed ID: 21532177
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term effects on vascular healing of bare metal stents delivered via paclitaxel-coated balloons in the porcine model of restenosis.
    Cremers B; Milewski K; Clever YP; Aboodi MS; Biedermann M; Thim T; Kelsch B; Kaluza GL; Scheller B; Granada JF
    Catheter Cardiovasc Interv; 2012 Oct; 80(4):603-10. PubMed ID: 22511557
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Integrity(®) bare-metal coronary stent-induced platelet and endothelial cell activation results in a higher risk of restenosis compared to Xience(®) everolimus-eluting stents in stable angina patients.
    Szük T; Fejes Z; Debreceni IB; Kerényi A; Édes I; Kappelmayer J; Nagy B
    Platelets; 2016 Jul; 27(5):410-9. PubMed ID: 26765134
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enhancement of endothelialisation of coronary stents by laser surface engineering.
    Li L; Mirhosseini N; Michael A; Liu Z; Wang T
    Lasers Surg Med; 2013 Nov; 45(9):608-16. PubMed ID: 24037969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.